Tatyana Simuni

  • Professor, Neurology
  • Arthur C. Nielsen, Jr. Research Professorship in Parkinson's Disease and Movement Disorders, Neurology
  • 7898 Citations
19982023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Dr Simuni joined the faculty of the Northwestern University Feinberg school of Medicine in 2000 to build and lead a multidisciplinary movement disorders center that is recognized by the National Parkinson’s Foundation as a Center of Excellence and serves as a training model in the region. Her research interests are focused on development of disease modifying ( neuroprotective ) interventions in Parkinson’s disease (PD). She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological and surgical management of PD. As the Principal Investigator of the multicenter Parkinson Study Group (PSG) Phase II study of isradipine as potential disease modifying agent in early PD (STEADY PD) and more recently NET PD FS-Zone studies as well as a member of the Steering Committees on a number of national studies including PPMI, she has developed expertise in design and coordination of multicenter studies. She is actively involved with the PSG where she is an active member of three PSG working groups and Chair of the Classic Motor group. She serves on the Steering Committees for the National Parkinson Foundation.

Certifications and Licenses

Neurology

Training Experience

1994Residency, Temple University Hospital
1995Fellowship, Temple University Hospital

Education/Academic qualification

MD, Leningrad Medical School

… → 1985

Research interests

  • Clinical Trial Methodology
  • Drug Discovery
  • Movement Control

Fingerprint Dive into the research topics where Tatyana Simuni is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Parkinson Disease Medicine & Life Sciences
Deep Brain Stimulation Medicine & Life Sciences
Movement Disorders Medicine & Life Sciences
Dopamine Plasma Membrane Transport Proteins Medicine & Life Sciences
Quality of Life Medicine & Life Sciences
Levodopa Medicine & Life Sciences
Subthalamic Nucleus Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2001 2023

Research Output 1998 2020

1 Citation (Scopus)
Dopamine Plasma Membrane Transport Proteins
Parkinson Disease
Cross-Sectional Studies
Mutation
Corpus Striatum

Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists (Genetics in Medicine, (2019), 10.1038/s41436-019-0684-x)

Alcalay, R. N., Kehoe, C., Shorr, E., Battista, R., Hall, A., Simuni, T., Marder, K., Wills, A. M., Naito, A., Beck, J. C., Schwarzschild, M. A. & Nance, M., Feb 1 2020, In : Genetics in Medicine. 22, 2, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Health Knowledge, Attitudes, Practice
Movement Disorders
Genetic Testing
Parkinson Disease
Medicine

Changes in Prescribing Practices of Dopaminergic Medications in Individuals with Parkinson's Disease by Expert Care Centers from 2010 to 2017: The Parkinson's Foundation Quality Improvement Initiative

the Parkinson's Foundation Quality Improvement Initiative Investigators, Jan 1 2019, (Accepted/In press) In : Movement Disorders Clinical Practice.

Research output: Contribution to journalArticle

Dopamine Agonists
Quality Improvement
Parkinson Disease
Disruptive, Impulse Control, and Conduct Disorders
Monoamine Oxidase Inhibitors

Clinical trial highlights: Targetting alpha-synuclein

McFarthing, K. & Simuni, T., Jan 1 2019, In : Journal of Parkinson's disease. 9, 1, p. 5-16 12 p.

Research output: Contribution to journalReview article

alpha-Synuclein
Clinical Trials

Clinical trial highlights: Phase III study in spotlight

McFarthing, K. & Simuni, T., Jan 1 2019, In : Journal of Parkinson's disease. 9, 1, p. 3-4 2 p.

Research output: Contribution to journalComment/debate

Phase III Clinical Trials